Product Launch

Pre-fillable Glass Syringe Systems

Silicone Oil-Free

for biotech, ophthalmics, and vaccines highly sensitive to silicone oil

Excellent drug-container compatibility

 Silicone oil-free syringe system

Silicone oil-free barrel | Silicone oil-free plunger stopper

 Minimized particle level

Stringent inspection for glass particles | Strict control of foreign matter

 Reduced or no risk of interactions due to tungsten

Controlled low level of tungsten | Tungsten-free luer syringes

Smooth integration into auto-injection devices

 Exact fit into auto-injection devices

Highly precise syringe dimensions | Controlled rigid needle shield concentricity and barrel bowing

 Complete dose delivery and precise injection time

Low break-loose force | Consistent plunger gliding force

 Supports safe operation of injection mechanisms

Strong finger flange | 100% in-line X-Ray inspection prevents pierced rigid needle shields (no unseen CCI)

Optimized processability for minimal drug loss

Reduced risk of final rejects due to cosmetic or dimensional aspects

100% in-line camera inspection of cosmetic and dimensional quality (incl. consistent flange restriction) | Rigid needle shield/closure intact and straight | Minimized particle level

Increased mechanical durability minimizes risk of breakage

Excellent quality of NSV51 glass (consistent wall thickness, minimal cosmetic defects: stones, knots, inclusions, etc.) | Laser-based cutting for increased mechanical durability of finger flanges

Reliable processability of D2F™ tubs

EtO indicator prevents entrance of unsterile tubs | Automatic bagger ensures integrity of breather bag and optimal processability on filling line

Go to article: Home | Inside the world of priority review vouchers where time is moneyGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: Lactalis IngredientsGo to article: In DepthGo to article: Inside the world of priority review vouchers where time is money Go to article: Quality and sustainability: The balancing act for pharma manufacturingGo to article: 2023 in review: Cancer vaccines dose up on advances with tailored approachesGo to article: Diversity and ePROs: Still siloed concepts in the era of DCTs? Go to article: Q&A: Tackling the rise of fake anti-obesity drugs on the market Go to article: Patching the problem of EU drug shortagesGo to article: Out-of-spec cell therapy manufacturing: an ethical dilemma for CDMOs and doctorsGo to article: NiproGo to article: phasetwoGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: Foreword: What’s next for the Internet of ThingsGo to article: An introduction to the Internet of Things Go to article: The digital ecosystem of the IoTGo to article: Timeline: Internet of ThingsGo to article: The impact of IoT on the pharma industry Go to article: Applications of IoT in the pharma industryGo to article: Latest news: IoT in pharmaGo to article: Analyst Q&A: IoT in pharmaGo to article: Bupa leverages unique position to develop IoT and AI features Go to article: IoT innovation: Leading companies in microneedles for transdermal drug deliveryGo to article: IoT in the pharmaceutical industry: analysing innovation, investment and hiring trendsGo to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: Avenga Company InsightGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue